Title : Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.

Pub. Date : 2020 Dec 11

PMID : 33308138






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Several clinical trials with a variety of drugs have failed, and the only Food and Drugs Administration (FDA) approved drug to treat ADPKD to date is tolvaptan that works by antagonizing the vasopressin-2 receptor (V2R). Tolvaptan arginine vasopressin receptor 2 Homo sapiens